GLPwatch
Mounjaro for Polycystic ovary syndrome
tirzepatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCMounjaro (tirzepatide) is not FDA-approved for polycystic ovary syndrome, and any use for this condition is off-label or investigational. Research includes animal studies and reviews suggesting potential benefits, but no clinical evidence in humans is provided.
AI summary of the sources below.
| Drug | Mounjaro (tirzepatide) |
|---|---|
| Condition | Polycystic ovary syndrome |
| Approval status | Investigational / off-label |
| Research papers | 5 |
Mounjaro is not FDA-approved for polycystic ovary syndrome; the research below reflects investigational or off-label study only.
Research on tirzepatide for polycystic ovary syndrome (5)
- Comparative effectiveness of semaglutide <i>versus</i> liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis.
- Adropin/Tirzepatide Combination Mitigates Cardiac Metabolic Aberrations in a Rat Model of Polycystic Ovarian Syndrome, Implicating the Role of the AKT/GSK3β/NF-κB/NLRP3 Pathway.
- Comparative Gynecological Safety of the Dual GIP/GLP-1 Receptor Agonist Tirzepatide vs. the GLP-1 Receptor Agonist Semaglutide: A Real-World Pharmacovigilance Analysis (2022-2025).
- Semaglutide and Tirzepatide for the Treatment of Obesity and Weight-Related Comorbidities: A Narrative Review.
- Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.